Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherrie L Kelly

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
AIDS (London, England)|January 22, 2019
Applying the 'no-one worse off' criterion to design Pareto efficient HIV responses in Sudan and TogoRobyn M Stuart, Hassan Haghparast-Bidgoli, Jasmina Panovska-Griffiths, et al.
PLOS Global Public Health|August 4, 2025
Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burdenJosephine Malinga, Lydia Braunack-Mayer, Thiery Masserey, et al.
Scientific Reports|January 25, 2023
Frequent and unpredictable changes in COVID-19 policies and restrictions reduce the accuracy of model forecastsFarah Houdroge, Anna Palmer, Dominic Delport, et al.
Journal of the International AIDS Society|March 7, 2018
A tale of two countries: progress towards UNAIDS 90-90-90 targets in Botswana and AustraliaTafireyi Marukutira, Mark Stoové, Shahin Lockman, et al.
Plos One|May 26, 2022
Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling studyDebra C Ten Brink, Rowan Martin-Hughes, Mark E Minnery, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2002
HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree communityBarbara L Triggs-Raine, Robert D Kirkpatrick, Sherrie L Kelly, et al.
The Lancet. HIV|September 8, 2024
Optimising HIV spending in 12 eastern European and central Asian countries: a modelling studyDebra C Ten Brink, Anna L Bowring, Rowan Martin-Hughes, et al.
Vaccine|November 15, 2025
Value profile for Malaria vaccines and monoclonal antibodiesAshley J Birkett, Evelyn Ansah, Scott Gordon, et al.
Plos One|February 17, 2017
Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficienciesAndrew J Shattock, Clemens Benedikt, Aliya Bokazhanova, et al.
The Lancet. Global Health|August 12, 2022
Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical modelsAnna Bershteyn, Lise Jamieson, Hae-Young Kim, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|January 22, 2019
Applying the 'no-one worse off' criterion to design Pareto efficient HIV responses in Sudan and TogoRobyn M Stuart, Hassan Haghparast-Bidgoli, Jasmina Panovska-Griffiths, et al.
PLOS Global Public Health|August 4, 2025
Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burdenJosephine Malinga, Lydia Braunack-Mayer, Thiery Masserey, et al.
Scientific Reports|January 25, 2023
Frequent and unpredictable changes in COVID-19 policies and restrictions reduce the accuracy of model forecastsFarah Houdroge, Anna Palmer, Dominic Delport, et al.
Journal of the International AIDS Society|March 7, 2018
A tale of two countries: progress towards UNAIDS 90-90-90 targets in Botswana and AustraliaTafireyi Marukutira, Mark Stoové, Shahin Lockman, et al.
Plos One|May 26, 2022
Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling studyDebra C Ten Brink, Rowan Martin-Hughes, Mark E Minnery, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2002
HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree communityBarbara L Triggs-Raine, Robert D Kirkpatrick, Sherrie L Kelly, et al.
The Lancet. HIV|September 8, 2024
Optimising HIV spending in 12 eastern European and central Asian countries: a modelling studyDebra C Ten Brink, Anna L Bowring, Rowan Martin-Hughes, et al.
Vaccine|November 15, 2025
Value profile for Malaria vaccines and monoclonal antibodiesAshley J Birkett, Evelyn Ansah, Scott Gordon, et al.
Plos One|February 17, 2017
Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficienciesAndrew J Shattock, Clemens Benedikt, Aliya Bokazhanova, et al.
The Lancet. Global Health|August 12, 2022
Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical modelsAnna Bershteyn, Lise Jamieson, Hae-Young Kim, et al.
Pageof 5